Tredence Buys KMK Consulting to Boost Healthcare AI Ambitions
Event summary
- Tredence acquired KMK Consulting on June 22, 2026 for undisclosed terms.
- KMK brings deep expertise in life sciences analytics and works with 8 of the top 10 pharmaceutical companies.
- Tredence aims to make healthcare & life sciences (HLS) 25% of its revenue by 2028.
- The deal strengthens Tredence's position within the Veeva ecosystem, used by 60-70% of global pharma firms.
The big picture
The deal comes as pharmaceutical companies accelerate AI investments, with the global market for AI in life sciences expected to reach $69.3 billion by 2031. By combining KMK's domain expertise with Tredence's applied AI capabilities, the acquisition positions Tredence to capture value across the entire molecule-to-market journey. The move also underscores how deep industry knowledge is becoming a key differentiator as agentic AI commoditizes traditional services.
What we're watching
- Integration Challenges
- How Tredence will merge KMK's domain expertise with its AI capabilities to create differentiated offerings.
- Revenue Targets
- Whether Tredence can achieve its 25% HLS revenue goal by 2028 given current market dynamics.
- Competitive Positioning
- The pace at which this acquisition will solidify Tredence's lead in AI-driven life sciences solutions.
Related topics